Ignite Creation Date:
2024-05-06 @ 5:42 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05409222
Status:
UNKNOWN
Last Update Posted:
2022-06-08
First Post:
2021-03-13
Brief Title:
Study of Quality of Life Post Salpingo-oophorectomy in BRCA12 PALB2 Mutation Carriers BRCA-HRT
Sponsor:
Fundació Institut de Recerca de lHospital de la Santa Creu i Sant Pau
Organization:
Fundació Institut de Recerca de lHospital de la Santa Creu i Sant Pau
Study Overview
Official Title:
Study of Quality of Life Post Preventive Salpingo-oophorectomy in Healthy BRCA12 and PALB2 Mutation Carriers
Status:
UNKNOWN
Status Verified Date:
2022-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRCA-HRT
Brief Summary:
1 Premenopausal BRCA1 2 or PALB2 gene mutation carriers who receive hormone replacement therapy HRT after preventive salpingo-oophorectomy PBSO have a better quality of sexual psychological cardiovascular and bone health than carriers who decline HRT
2 Premenopausal mutation carriers treated with PBSO who choose HRT have a comparable overall survival and specific survival for breast gynecological cancer to women who undergo surgery and refuse to receive HRT
3 Premenopausal mutation carriers treated with PBSO have better overall and specific breast gynecological cancer survival than non-SOBP carriers
2 Premenopausal mutation carriers treated with PBSO who choose HRT have a comparable overall survival and specific survival for breast gynecological cancer to women who undergo surgery and refuse to receive HRT
3 Premenopausal mutation carriers treated with PBSO have better overall and specific breast gynecological cancer survival than non-SOBP carriers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None